StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)

Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –

Rallybio price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Rallybio's price to sales ratio was 129.8× on Nov 11, 2026, against 40.5× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026129.8×+87.1
2025Dec 31, 202542.7×–

More Rallybio figures

See a number that looks wrong?